Xifaxan in 2026: What's the Current Situation?

If you rely on Xifaxan (Rifaximin) to manage hepatic encephalopathy, IBS-D, or another GI condition, you've probably experienced the frustration of trying to fill your prescription. Phone call after phone call, pharmacy after pharmacy — and still no luck.

So what's actually going on with Xifaxan in 2026? Is there a true shortage, or something else? Let's get into it.

Is Xifaxan in Shortage Right Now?

As of February 2026, Xifaxan is not listed on the FDA's official drug shortage database. That means there's no formal, recognized manufacturing or supply shortage for Rifaximin.

But here's the catch: the FDA shortage list only tracks manufacturing disruptions reported by drug companies. It doesn't capture the day-to-day reality of patients who can't find a medication at their local pharmacy. And for Xifaxan, that reality is very real.

The disconnect comes from what we might call a practical shortage — the drug exists in the supply chain, but a combination of factors makes it hard for individual patients to access it at their local pharmacy.

Why Is Xifaxan So Hard to Find?

Several factors contribute to the ongoing difficulty:

Extremely High Cost

Xifaxan 550 mg costs $1,600 to $2,200 for a one-month supply without insurance. For an IBS-D treatment course (14 days), it's $1,400 to $1,800. Many pharmacies simply won't stock a medication this expensive unless they have a confirmed, paid order. The financial risk of holding unsold inventory is too high.

No Generic Available

Rifaximin is still under patent protection, with exclusivity expected through 2028–2029. There's only one manufacturer — Salix Pharmaceuticals (Bausch Health) — which means no competition and no lower-cost alternatives that pharmacies could substitute.

Insurance Barriers

Even patients with insurance often face delays. Xifaxan typically sits on Tier 3 or specialty tier formularies, and many plans require prior authorization. For hepatic encephalopathy, some insurers mandate a trial of Lactulose first (step therapy). These administrative hurdles can take days or weeks to resolve — during which time you're without your medication.

Growing Demand

With increasing awareness of conditions like SIBO (small intestinal bacterial overgrowth), Xifaxan prescriptions have grown beyond its three FDA-approved uses. More demand on a single-source brand-name drug stretches supply in certain regions.

For a deeper dive, read our post on why Xifaxan is so hard to find.

What Does Xifaxan Cost in 2026?

Here's what you can expect to pay:

• Hepatic encephalopathy (550 mg twice daily, ongoing): $1,600–$2,200/month cash price
• IBS-D (550 mg three times daily for 14 days): $1,400–$1,800 per course
• Travelers' diarrhea (200 mg three times daily for 3 days): Approximately $60–$100

With the manufacturer's copay savings card, commercially insured patients may pay as little as $0. Without insurance, the Bausch Health Patient Assistance Program may cover the full cost for qualifying patients.

For a complete breakdown of savings options, see our guide: How to save money on Xifaxan.

Are There Any New Options in 2026?

Unfortunately, the landscape hasn't changed dramatically:

• No generic Rifaximin yet. The earliest expected launch remains 2028–2029.
• No new direct competitors. Xifaxan remains the only non-absorbable rifamycin antibiotic approved in the U.S.
• Lactulose remains the primary alternative for hepatic encephalopathy, available generically for $15–$60/month.
• For IBS-D, Viberzi (Eluxadoline) and Alosetron (Lotronsa) remain available alternatives, though they work through different mechanisms.

If you need to explore alternatives, our guide on Xifaxan alternatives covers each option in detail.

How to Find Xifaxan in Stock Right Now

Here's your action plan:

1. Search on Medfinder: Check real-time pharmacy availability near your zip code. This is the fastest way to find Xifaxan in stock without calling around.
2. Try independent pharmacies: They're often more willing to special-order expensive medications than chain pharmacies.
3. Consider mail-order: Many insurance plans cover Xifaxan through mail-order pharmacy with potentially lower copays.
4. Ask about samples: Your gastroenterologist or hepatologist may have Xifaxan samples to bridge a short gap.
5. Apply for savings programs: The Xifaxan copay card or patient assistance program can remove the cost barrier that keeps many pharmacies from stocking the drug.

For a full walkthrough, see our guide on how to find Xifaxan in stock near you.

Final Thoughts

Xifaxan isn't in a formal shortage, but for many patients, it might as well be. The combination of a sky-high price, no generic competition, and insurance red tape creates a perfect storm of inaccessibility.

The best thing you can do is stay proactive: use tools like Medfinder, explore savings programs, and keep an open line of communication with your doctor about backup plans. A generic Rifaximin may finally arrive in the next few years, but until then, persistence is your best prescription.